This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
ISPOR Europe 2024 Poster Presentations
The Catalyst Flex medical writing team was honored to have our posters presented at ISPOR Europe 2024!
Catalyst Flex is thrilled to showcase eight innovative posters that delve into the latest advancements and research in the field of real-world evidence (RWE) and health economics and outcomes research (HEOR). These posters highlight our commitment to excellence and our dedication to improving patient outcomes.
Discover how our cutting-edge research makes a difference and drives progress.
Economic Evaluation of Digital Health Interventions in Oncology (MT26)
Digital health interventions are transforming patient care and enhancing outcomes in oncology.
Cost-effectiveness analysis, though essential for decision-making in oncology, remains underexplored in the digital health domain.
This review underscores significant evidence gaps in the cost-effectiveness of digital health solutions within oncology.
The findings aim to inspire oncologists to integrate digital health into practice, fostering both improved patient journeys and further HEOR research in this evolving field.
Epidemiology Information Synthesis for Focal Segmental Glomerulosclerosis (MSR182)
Synthesizing epidemiology data for rare diseases like FSGS is complex, highlighting the need for an intelligent solution.
Our approach integrates people, streamlined processes, and an innovative product to tackle these challenges.
Leveraging AI/ML, this tool enhances accuracy and efficiency in evidence synthesis for rare disease epidemiology.
This research framework sets a blueprint for developing similar tools across rare diseases in the epidemiology space.
Exploring the Relationship Between Genetic Heterogeneity and Acquired Resistance to Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer: A Targeted Literature Review (HPR48)
Genetic heterogeneity in NSCLC contributes to treatment resistance against immune checkpoint inhibitors (ICIs).
Our review synthesizes evidence on how patient variability, molecular profiles, and personalized treatment strategies impact ICI outcomes.
Insights from literature reveal associations between genetic factors and ICI resistance, underscoring the role of genomic profiling.
This research encourages precision oncology approaches to address treatment disparities in NSCLC by identifying genetic predictors of resistance.
Adopting ICH M11 CeSHarP Guidelines for Oncology Protocol Digitalization (HPR148)
Oncology protocol development is intricate, requiring precision from dedicated protocol teams and medical writers.
As the need for rapid cancer treatment advancements grows, innovative methods are essential to streamline protocols.
Protocol digitalization, supported by CeSHarP M11 guidelines, enables standardized, digitized protocol content.
This research explores how CeSHarP M11 can tackle challenges in oncology, from complex methodologies to unstructured content and varied patient needs.
Oncology-specific Considerations in Conduct of Pragmatic Trials (SA21)
Pragmatic trials assess real-world effectiveness, focusing on diverse patient populations in typical clinical settings.
Integrating pragmatic elements into drug development can accelerate new therapies and ensure clinical relevance.
Limited guidance on oncology pragmatic trials creates challenges for robust, reliable methodologies.
This registry audit aims to assess the methodological aspects of these trials to inform future real-world evidence (RWE) methodology guidance in oncology.
CAR T-Cell Therapy and the Emerging Threat of Secondary Cancers (CO34)
CAR T therapy improves survival in blood cancers but may raise the risk of secondary malignancies.
Our analysis found secondary malignancies in a small subset of CAR T-treated patients, with hematological cancers being the most common.
Key risk factors for these cancers may include prior treatments, immune suppression, and follow-up duration.
There is a data gap and lack of monitoring guidelines. Our research highlights the need for long-term monitoring and further studies to manage risks and optimize CAR T therapy.
Exploring the Clinical Translation of Synthetic Lethality, PRMT5 Inhibitors in MTAP Depleted Cancers (SA92)
Synthetic lethality (SL) occurs when two genetic events together cause cell death, a principle successfully applied in PARP inhibitor therapy for BRCA-mutated cancers.
Targeting protein arginine methyltransferase 5 (PRMT5) in oncology is promising due to its involvement in S-adenosylmethionine production.
This strategy exploits SL in cancers lacking methylthioadenosine phosphorylase (MTAP), a key enzyme in the methionine salvage pathway.
This scoping review examines studies and technologies focused on PRMT5 inhibition as a therapeutic approach for MTAP-deleted cancers.
Assessing and Reporting HR-QOL in Pediatrics with Cystic Fibrosis (PCR150)
Early complications in children with cystic fibrosis (CF) can cause disruptions in growth and development, highlighting necessity of prioritizing pediatric assessments with focus on humanistic outcome research.
Despite substantial evidence on humanistic consequences of CF clinical symptoms in children and recommendations from regulatory guidelines, the current CF research has limited emphasis on assessing HR-QoL.
The current review identifies concerning underreporting of HR-QoL in clinical trials and examines variability in tools and methods employed for measuring HR-QoL.
The findings indicate pressing need for standardized HR-QoL assessment tool tailored specifically for pediatric CF patients as well as integrating HR-QoL evaluations into routine clinical assessments.